The Centers for Medicare and Medicaid Services (CMS), the federal health insurance program for people 65 plus, announced its decision to deny covering Biogen’s Aduhelm and all future anti-amyloid treatments under what is known as a Coverage with Evidence Development (CED).  What does this first-round decision mean? 

BrainStorm host, Meryl Comer, and guest, Stephanie Monroe, Executive Director of AfricanAmericansAgainstAlzheimer's and Co-Director of the Center for Brain Health Equity discuss the underlying issues that she calls discriminatory, particularly for communities of color.  

Russ Paulsen, Chief Operating Officer at UsAgainstAlzheimer’s, offers a statement on why UsAgainstAlzheimer’s opposes the CMS decision and provides a statement explaining what this means for those living with Alzheimer’s. 

The proposed National Coverage Determination is open to public comment for 30 days (until Feb 9). A final decision will be announced in April. 

Support the show (https://www.usagainstalzheimers.org)